Madan, A., Zhu, Y. F., Markison, S., Betz, S., Krasner, A., Luo, R., . . . Struthers, S. (2019). SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers. J Endocr Soc.
Čikaški stil citiranjaMadan, Ajay, et al. "SAT-429 Final Results From the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable Sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers." J Endocr Soc 2019.
MLA način citiranjaMadan, Ajay, et al. "SAT-429 Final Results From the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable Sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers." J Endocr Soc 2019.